EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer
Published on July 14, 2026
WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company and developer of therapeutics for patients with serious retinal diseases, has announced the appointment of Tarek S. Hassan, MD, as senior vice president, chief strategic science officer. Dr. Hassan will report directly to Jay S. Duker, MD, president and CEO of EyePoint, and will serve as a member of the executive leadership team, according to the announcement. A globally recognized retina specialist with more than 35 years of experience, Dr. Hassan will provide strategic guidance across the company’s portfolio to optimize development, potential commercialization, and growth opportunities for EyePoint’s pipeline, including its lead program, Duravyu (vorolanib intravitreal insert).